Weekly ReportJul 6–12, 2026
Anesthesiology, week 28 edition
We read 561 papers and selected 3.
Summary
This week’s most consequential findings challenged established perioperative and critical care practices while advancing precision monitoring. The RATE randomized trial showed that low-dose unfractionated heparin and therapeutic low-molecular-weight heparin were noninferior to standard-dose heparin during ECMO, with numerically less severe bleeding. Augmented-reality lung nodule localization achieved noninferior resection success while substantially reducing radiation, pain, and workflow delays. Additional studies highlighted the value of patient-centered opioid tapering without assuming routine behavioral add-ons improve success, and expanded the use of frailty, EEG, echocardiographic, immune-endothelial, and microcirculatory markers for individualized risk assessment.
Selected Articles
1. Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.
In the multicenter RATE randomized noninferiority trial, low-dose unfractionated heparin and therapeutic low-molecular-weight heparin were noninferior to standard-dose unfractionated heparin for a composite of severe bleeding, severe thromboembolism, or 6-month mortality in ECMO patients. Severe bleeding was numerically lower with both reduced-intensity strategies, without an excess of thromboembolic events.
Impact: This is the first sufficiently powered randomized trial to directly test anticoagulation intensity during ECMO, addressing a common practice with major bleeding consequences.
Clinical Implications: ECMO programs may consider lower-intensity UFH or therapeutic LMWH in patients without a compelling indication for full-dose anticoagulation, while maintaining individualized monitoring for bleeding and thrombosis.
Key Findings
- Low-dose UFH and therapeutic LMWH met the prespecified noninferiority criterion versus standard-dose UFH.
- Severe bleeding occurred in 58% with low-dose UFH, 59% with LMWH, and 65% with standard-dose UFH.
- Severe thromboembolism was not increased with reduced-intensity anticoagulation.
2. Single-Encounter Augmented Reality-Guided Localization for Resection of Suspected Early-Stage Lung Cancer: A Randomized Clinical Trial.
In a five-center randomized noninferiority trial, single-encounter augmented-reality-guided localization achieved noninferior successful sublobar resection compared with conventional multiple-encounter CT-guided localization. The AR workflow substantially reduced radiation exposure, preoperative pain, puncture time, and localization-to-incision delay.
Impact: The study provides randomized evidence that a technology-enabled, operating-room-based workflow can preserve surgical accuracy while reducing patient burden and resource use.
Clinical Implications: AR-guided localization may be considered for suitable small pulmonary nodules, particularly where reducing CT-suite use, radiation, procedural pain, and delays is clinically valuable. Local expertise and margin protocols remain essential.
Key Findings
- Successful sublobar resection was 98.5% with AR versus 99.3% with CT guidance, meeting noninferiority.
- Median radiation exposure was 456.5 versus 1260.1 mGy·cm with AR and CT, respectively.
- AR reduced preoperative pain, puncture time, and localization-to-incision interval.
3. Patient-Centered Prescription Opioid Tapering Methods : A Randomized Clinical Trial.
In an 11-site randomized trial of 562 adults receiving long-term prescription opioids, adding pain-focused cognitive behavioral therapy or a chronic pain self-management program did not improve 12-month taper success compared with patient-centered tapering alone. Taper success was approximately 51% with tapering alone, while CBT was associated with fewer study-related adverse events and withdrawal symptoms.
Impact: This pragmatic randomized trial provides important negative evidence against assuming that routine behavioral add-ons improve opioid tapering, while identifying a possible safety benefit of CBT.
Clinical Implications: Clinicians can prioritize individualized tapering plans, close monitoring, and patient engagement rather than requiring routine CBT or self-management programs for all patients. CBT may be selectively offered to patients at higher risk of withdrawal-related problems.
Key Findings
- Taper success at 12 months was 50.9% with tapering alone, 48.6% with CBT, and 44.5% with self-management.
- Neither behavioral intervention significantly improved taper success over tapering alone.
- Study-related adverse events were most frequent with tapering alone: 66% versus 54% with CBT.